New drug cocktail aims to shrink lung tumors after standard treatment fails
NCT ID NCT04332367
First seen Jan 11, 2026 · Last updated Jun 22, 2026 · Updated 22 times
Summary
This phase 2 trial is testing whether combining three anti-cancer drugs—carboplatin, paclitaxel, and ramucirumab—can shrink tumors or slow their growth in people with advanced non-squamous non-small cell lung cancer. The study enrolls adults whose cancer has progressed after at least 18 weeks of maintenance therapy with pemetrexed and/or pembrolizumab. Researchers will also monitor safety and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Abramson Cancer Center of the University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
carboplatin, paclitaxel, and ramucirumab
What this could lead to
If successful, this drug combination could offer a new treatment option for people with advanced non-small cell lung cancer whose disease has worsened after initial therapy.
What could go wrong
This is a small, early-phase trial with only 59 participants, so results may not apply to everyone. The drugs can cause side effects like nerve damage and low blood counts.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.